JaswinderSinghMD

Oncology • Kansas City, MO

Gastrointestinal Cancer, Hematologic Oncology, Thoracic Cancer

Sarah Cannon Cancer Center

Join to view full profile

Dr. Singh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Singh's full profile

Already have an account?

Office
2316 E Meyer Blvd
# 1
Kansas City, MO 64132
Phone+1 816-276-4700

Fax+1 816-276-3810

Education & Training

University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 2005 - 2008
Icahn School of Medicine at Mount Sinai/NYC Health and Hospitals (Elmhurst)Residency, Internal Medicine, 1999 - 2002
Government Medical College ChandigrahClass of 1997

Certifications & Licensure

MO State Medical License 2002 - 2026
KS State Medical License 2005 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Asco

Clinical Trials

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary Start of enrollment: 2009 Feb 01
Completed
Phase 2
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study Start of enrollment: 2010 Mar 22
Completed
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
BGJ398 for Patients With Tumors With FGFR Genetic Alterations Start of enrollment: 2014 Jul 24
Terminated
Phase 2
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25
Completed
Phase 2
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
No longer available
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Start of enrollment: 2017 Jan 12
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

8 citations
Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenoca...
E Gabriela Chiorean, Vincent Picozzi, Chung-Pin Li, Marc Peeters, Joan Maurel
Cancer Medicine. 2023-10-01
9 citations
Desmoid type fibromatosis: A case report with an unusual etiology.
Syed Faisal Jafri, Obada Obaisi, Gerardo G Vergara, Joe Cates, Jaswinder Singh
World Journal of Gastrointestinal Oncology. 2017-09-15
30 citations
Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab ...
Johanna C. Bendell, Thomas J. Ervin, David Gallinson, Jaswinder Singh, James A. Wallace
Clinical Colorectal Cancer. 2013-09-01